Central Nervous System Effects of Metoclopramide

Mechanism and Clinical Manifestations

Nigrostriatal pathway antagonism leads to extrapyramidal symptoms and movement disorders, as reported by the Pediatrics journal in 2016 1

Acute dystonic reactions, including involuntary movements of limbs, facial grimacing, and oculogyric crisis, occur in approximately 0.2% of patients on standard doses, with a higher incidence in patients under 30, as noted in the Pediatrics journal in 2016 1
Life-threatening presentations, such as laryngeal dystonia causing stridor and dyspnea, can occur, as reported by the Pediatrics journal in 2016 1
Drug-induced parkinsonism, characterized by bradykinesia, tremor, and cogwheel rigidity, can occur, particularly in older patients on long-term therapy, as noted in the Pediatrics journal in 2016 1
Akathisia, a condition characterized by subjective symptoms of anxiety and agitation, and objective signs of inability to sit still, can occur, as reported by the Pediatrics journal in 2016 1

Tardive dyskinesia, a potentially irreversible condition, occurs in approximately 5% of young patients per year, with higher rates in older patients on prolonged therapy, as noted in the Pediatrics journal in 2016 1
Respiratory dyskinesia, a variant of tardive dyskinesia, can lead to recurrent aspiration pneumonia, as reported by the Pediatrics journal in 2016 1
Neuroleptic malignant syndrome, a rare but potentially lethal syndrome, requires immediate recognition and hospital treatment, as noted in the Pediatrics journal in 2016 1

The American Diabetes Association recommends limiting metoclopramide to ≤12 weeks for severe gastroparesis cases unresponsive to other therapies, with regular neurological monitoring for extrapyramidal symptoms, as reported in Diabetes Care in 2020 2
Concomitant psychotropic medications represent an especially high risk factor for neuroleptic malignant syndrome, with over half of cases involving concurrent psychotropic agents, as noted in the Pediatrics journal in 2016 1

The American Diabetes Association recommends metoclopramide for short-term treatment (≤12 weeks) of gastroparesis, reserving it for severe cases unresponsive to other therapies due to the risk of serious adverse effects 3, 4
The FDA recommends limiting metoclopramide use to ≤12 weeks due to the risk of tardive dyskinesia 3, 5

The American Gastroenterological Association suggests a low-fiber, low-fat eating plan with small, frequent meals as a first-line approach for gastroparesis, with metoclopramide trial as a second-line approach 3, 6
Metoclopramide can significantly accelerate gastric emptying in patients with diabetic gastroparesis, although the level of evidence regarding its benefits is considered weak 3, 4

The American College of Gastroenterology warns of a black box warning for metoclopramide due to the risk of tardive dyskinesia with long-term use or high doses 3
Other extrapyramidal symptoms include acute dystonic reactions, drug-induced parkinsonism, and akathisia 3

The treatment algorithm for gastroparesis involves dietary modifications as a first-line approach, followed by a metoclopramide trial as a second-line approach, and consideration of alternative treatments for medically refractory gastroparesis 3, 6
For severe cases of GERD with delayed gastric emptying that have failed standard therapy, metoclopramide may be considered, with the same dosing and duration restrictions as for gastroparesis 6

The American Diabetes Association recommends withdrawing medications that may adversely affect gastrointestinal motility, including opioids, anticholinergics, and GLP-1 receptor agonists, while balancing the risk of removing GLP-1 receptor agonists against their potential benefits 3, 7

The European Medicines Agency's Committee recommends that metoclopramide is not used in the long term due to extrapyramidal side effects and potentially irreversible tardive dyskinesia in elderly subjects, together with no evidence of consistent benefit in gastroparesis 8, 9, 10, 11